Company: MIRM
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0001759425-25-000032
Chunk: 384

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-05-07
Form: 10-Q
Item: Part I, Item 8
Chunk 384
---
,965 $— $— $202,965 U.S. treasury bills$2,957 $7 $— $2,964 Corporate debt securities$37,942 $50 $(14)$37,978 U.S. government bonds$26,819 $90 $(5)$26,904 Agency bonds$2,490 $2 $— $2,492 Total cash equivalents and investments$273,173 $149 $(19)$273,303 Classified as:Cash equivalents$202,965 Short-term investments57,812 Long-term investments12,526 Total cash equivalents and investments$273,303 As of March 31, 2025, the remaining contractual maturities of available-for-sale debt securities were as follows (in thousands):Estimated Fair ValueDue within one year$65,852 One to two years20,912 Total$86,764 

During the three months ended March 31, 2025 and 2024, there have been no significant realized gains or losses on available-for-sale investments, no investments have been in a continuous unrealized loss position for more than 12 months, and the Company did not recognize any material unrealized gains or losses on these securities. 

12

5. Balance Sheet Components

InventoryInventory consists of the following (in thousands): March 31,2025December 31,2024Raw materials$3,026 $3,030 Work in progress15,817 16,089 Finished goods3,575 3,284 Total inventory$22,418 $22,403 Intangible Assets, NetThe components of the Company’s intangible assets were as follows (in thousands, except for weighted-average remaining amortization period): March 31, 2025 Gross Carrying ValueAccumulated Amortization Net Carrying AmountWeighted-Average Remaining Amortization Period (Years)Commercial milestones$59,000 $(8,235)$50,765 12.3Developed technology226,620 (33,998)192,622 10.4Assembled workforce970 (512)458 1.4Total intangible assets$286,590 $(42,745)$243,845 10.8 December 31, 2024 Gross Carrying ValueAccumulated Amortization Net Carrying AmountWeighted-Average